It is generally accepted that vasculogenesis is limited to early embryogenesis and is believed not to occur in adult, whereas angiogenesis occurs in both the developing embryo and postnatal life. However, the distinction between them is not absolute, because both require endothelial cell proliferation and migration and three-dimensional reorganization of newly formed blood vessels, nor are they mutually exclusive, inasmuch as angioblasts can be incorporated into expanding pre-existing blood vessels. Recent observations indicate that vasculogenesis may not be restricted to early embryogenesis, but may also have a physiological role or contribute to the pathology of vascular diseases in adults. The major evidence in favor of this new view comes from: (i) demonstration of the presence of circulating endothelial cells and endothelial precursor cells; (ii) newly described mechanisms of blood vessel formation in tumor growth. The potential biomedical applications of endothelial precursor cells and the new opportunities for the development of new forms of tumor-targeted treatments are discussed. q
Introduction
The cardiovascular system is the ®rst functional organ system to develop in the vertebrate embryo. A widely accepted view is that blood vessels arise through two mechanisms during development, vasculogenesis and angiogenesis . New vessels in the adult arise mainly through angiogenesis, although vasculogenesis also may occur. The existence of a postnatal vasculogenesis is supported by the evidence that both endothelial cells (ECs) and endothelial precursor cells (EPCs) co-exist in the circulation. Moreover, EPCs are also recruited to sites of neovascularization in mature mammals from a circulating, marrow-derived population of progenitor cells (Asahara et al., 1997) . Although circulating ECs have been suspected to have the capacity to colonize vascular grafts (Shi et al., 1994; Ra®i et al., 1995) the contribution of these cells to postnatal vasculogenesis is not known. The possibility that EPCs, showing properties similar to those of embryonic angioblasts, persist into adult life whereby they may circulate, differentiate, and contribute to the formation of new blood vessels remains to be determined.
This overview summarize our present understanding of blood vessel formation and raise some outstanding questions related to postnatal vasculogenesis.
The orthodox view
During embryonal life, blood vessels ®rst appear as the result of vasculogenesis, i.e. the formation of capillaries from ECs differentiating in situ from groups of mesodermal cells. The primitive heart and primitive vascular plexus are formed in this way (Risau and Flamme, 1995) .
The term angiogenesis, applied to the formation of capillaries from pre-existing vessels, i.e. capillaries and postcapillary venules , is based on endothelial sprouting or intussusceptive (non-sprouting) microvascular growth (Ausprunk and Folkman, 1977; Burri and Tarek, 1990) (Fig. 1) .
The relative contribution of vasculogenesis and angiogenesis to establishment of the vasculature varies among different developing organs, depending on whether or not they contain angioblasts. The lung, for example, appears to be solely vascularized by vasculogenesis, the kidney and brain solely by angiogenesis . Nevertheless, this distinction is not absolute. As concerns the kidney vasculature, several morphological investigations (see for a review Hyink and Abrahamanson, 1995) considered two origins, by vasculogenesis and angiogenesis, of ECs in the embryonic kidney. It has been also proposed that the germ layer associated with the mesoderm determines the type of growth: in organs of endodermal origin (e.g. the lung), vasculogenesis is the rule, in those of ectodermal origin (e.g. the brain) angiogenesis is prevalent (Pardanaud et al., 1989) . Intussusceptive growth predominates in the lung, which is initially vascularized by vasculogenesis.
In postnatal life, angiogenesis forms the physiological process in the follicle and corpus luteum, uterus and placenta, during the ovarian and menstrual cycles and pregnancy, respectively, or it is associated with a pathological condition, chronic in¯ammation, such as diabetic retinopathy or rheumatoid arthritis, or neoplasia (Folkman, 1995) (Fig. 1) .
The distinction between vasculogenesis and angiogenesis is not absolute and they overlap. Both require ECs proliferation, migration, three-dimensional reorganization of newly formed aggregates and use similar extracellular matrix adhesive mechanisms . Moreover, vasculogenesis and angiogenesis are not mutually exclusive, inasmuch as angioblasts can be incorporated into expanding pre-existing blood vessels (Auerbach and Auerbach, 1997) .
Mechanisms of prenatal vasculogenesis
The most typical and earliest site of prenatal vasculogenesis are the blood islands in the yolk sac, composed of hemangioblasts, the putative common precursors of endothelial and hematopoietic cells (Choi et al., 1998) .
The peripheral cells of the blood islands connect to construct a primitive network composed of capillaries, arteries and veins. Flamme et al. (1997) showed that ®bro-blast growth factor-2 (FGF-2) induces pluripotent cells of the quail blastodisk to undergo vasculogenesis.
Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) are the ®rst EC-speci®c signal transduction pathways activated during vasculogenesis. VEGF-de®-cient embryos die between day 8.5 and 9.0 and their primitive vascular structures are severely defective (Carmeliet et al., 1996; Ferrara et al., 1996) , while VEGFR-2-de®-cient mice die early since blocked migration of angioblasts to the initial sites of vasculogenesis (Shalaby et al., 1995; . VEGFR-2 is highly expressed later in ECs (Millauer et al., 1993) , but downregulated in most hemopoietic cells (Kabrun et al., 1997) . ECs develop in VEGFR-1-de®cient embryos, but death before day 9.5 still occurs due to the defective organization of the primitive vascular system (Fong et al., 1995) . Inactivation of the gene for VEGFR-3 also affects lumen formation in large vessels during early development (Dumont et al., 1998) . Early microinjection of VEGF into quail embryos caused vasculogenesis in normally avascular areas, while the normal polygonal pattern of vessel characteristic of early embryos was replaced by abnormal, enlarged vascular channels .
Another receptor-ligand system, Tie-1 and Tie-2, is important in embryonic vascular development. Vasculogenesis proceeds normally in embryos lacking both Tie-1 and Tie-2, although they die early due to multiple cardiovascular defects (Suri et al., 1996; Puri et al., 1999) . Knockout embryos lacking angiopoietin-1 (Ang-1), an activator of Tie-2, display failure of EC adherence and interaction with perivascular cells and extracellular matrix (Davis and Yancopoulos, 1999) . Transgenic overexpression of Ang1 in skin results in pronounced hypervascularization (Thurston et al., 1999; Suri et al., 1998) .
Integrins, which are cell surface heterodimers, play a critical role in angiogenesis (Brooks et al., 1994; Brooks, 1996) . Integrin a v b 3 is highly expressed on angioblasts and an a v b 3 antagonist, LM 609, prevents the maturation of primordial ECs into blood vessels . b 1 integrin, too, plays a pivotal role in vasculogenesis; when avian embryos are injected with the anti-b 1 integrin antibody CSAT, they display only cordlike assemblies of ECs at stages and in positions where normal vessels with a lumen should have formed (Drake et al., 1992) .
Postnatal vasculogenesis
Recent evidence indicates that vasculogenesis may not be restricted to early embryogenesis, but may also have a physiological role, contributing to the pathology of vascular diseases in postnatal life. This comes from observations that both ECs and EPCs co-exist in the circulation and that blood vessels can emerge in a new way during tumor growth (Fig.  1 ).
Circulating ECs and EPCs
Circulating ECs was ®rst demonstrated in the 1960s by several investigators using Dacron grafts placed in the pig, rabbit and dog (Stump et al., 1963; Gonzales et al., 1969) . ECs lining the coronary arteries of a transplanted human heart were shown to be derived from the recipient and not the donor (Kennedy and Weissman, 1971) . Further, ECs have been shown to line a ventricular assist device (Frazier et al., 1993) . In this context it is interesting that circulating ECs were detectable in pathological diseases marked by vascular injury conditions, namely sickle cell anemia, acute myocardial infarction, thrombotic thrombocytopenic purpura, and active cytomegalovirus infection (Solovey et al., 1997; Hladovec et al., 1978; Lefevre, 1993; Grefte et al., 1993) . Normal adults have 2.6^1.6 circulating ECs per mm of peripheral blood (Solovey et al., 1997) and most of these cells are quiescent, and at least half are microvascular as de®ned by CD36 positivity (Solovey et al., 1997) . These results are all consistent with the hypothesis that circulating EPCs form a monolayer on a graft surface.
Speci®c and non-speci®c markers of circulating EPCs
Currently, there has been no exclusive marker for EPCs. Both EPCs and mature ECs may express similar endothelial-speci®c markers, including VEGFR-2 (Eichmann et al., 1997) , Tie-1 (Sato et al., 1993) , Tie-2 and VE-cadherin (Vittet et al., 1997; Ali et al., 1997) . Identi®cation of differences between EPCs and circulating mature ECs is further complicated by the fact that hematopoietic cell subsets express markers similar to those of ECs, such as CD34, platelet endothelial cell adhesion molecule (PECAM), tyrosine kinase receptors such as Tie-1, Tie-2, Eph and VEGR-1, transcription factors such as SCL/tal-1 and AML1, von Willebrand factor (vWF) (Ziegler et al., 1999; Suda et al., 2000) . Asahara et al. (1997) , by using a polyclonal antibody to the intracellular domain of VEGFR-2, showed that CD34 1 , VEGFR-2 1 circulating EPCs form colonies, that take up acetylated LDL. When CD34
-or VEGFR-2 -cells were injected into mice, rats, and rabbits undergoing neovascularization due to hindlimb hischemia, CD34
1 and VEGFR-2 1 cells, but rarely CD34 -or VEGFR-2 -cells, incorporate into the vasculature in manner consistent with their being EC (Asahara et al., 1997) .
A novel hematopoietic stem cell marker, AC 133, which function is unknown, is also expressed on subsets of EPCs, but not on mature ECs . Expression of AC 133 is rapidly downregulated as hematopoietic progenitors and EPCs differentiate Yin et al., 1997) . Furthermore, Peichev et al. (2000) have demonstrated that a small subset of CD34 Recently, it has been reported that AML1 is expressed in ECs in sites were early hematopoietic stem cells emerge, such as the yolk sac (North et al., 1999) . AML1 de®cient embryos, which lack de®nitive hematopoiesis, showed also defective angiogenesis in the head and pericardium (Takamura et al., 2000) .
The source of circulating EPCs
EPCs present in the peripheral blood may derive from the bone marrow and not yet be incorporated into the vessel wall. Several lines of evidence suggest that EPCs constitute the preponderance of circulating bone marrow-derived endothelial lineage cells. The most striking experimental data are summarized. Asahara et al. (1999a,b) , utilizing a bone marrow transplant model in mice sublethally irradiated, demonstrated the incorporation of bone marrow EPCs into foci of neovascularization. Four weeks after transplants, when the bone marrow has been reconstituted, a variety of surgical experiments to provoke neovascularization were performed: (a) Cutaneous wounds examined 4 and 7 days after skin removal by punch biopsy disclosed a highly frequency of incorporated EPCs. (b) One week after the onset of hindlimb ischemia, EPCs were incorporated in capillaries among skeletal myocytes. (c) After permanent ligation of a coronary artery, myocardial infarction sites demonstrated incorporation of EPCs in foci of neovascularization at the border of the infarct. All these ®ndings clearly indicate that postnatal neovascularization does not solely rely angiogenesis and that EPCs from bone marrow contribute to postnatal vasculogenesis. Shi et al. (1994) implanted a Dacron graft made impermeable in the canine thoracic aorta and demonstrated scattered islands of ECs without any evidence of transmural angio-genesis. Later, they used a transplantation model in which marrow cells from donors and recipients were distinguishable to determine whether ECs lining a vascular prosthesis are derived from the bone marrow (Shi et al., 1998) . After 12 weeks, the graft was retrieved, and cells with endothelial morphology were identi®ed; only donor alleles were detected in DNA from positively stained cells on the graft. These results suggested that a subset of CD34 1 cells located in the bone marrow mobilize to the peripheral circulation and colonize the endothelial¯ow surface of vascular prostheses. Lin et al. (2000) distinguished in blood samples from bone marrow transplants recipients, who had received gender-mismatched transplants 5±20 months earlier, between vessel wall and bone marrow-derived ECs. They showed that 95% of circulating ECs detectable in blood had recipient genotype, while 5% ECs showed donor genotype. After 9 days of culture, ECs, derived predominantly from the recipient vessel wall, undergo only 6-fold expansion, whereas ECs after 27 days of culture, mostly originated from donor bone marrow cells, undergo 98-fold expansion. These data suggest that most circulating ECs in fresh blood originate from vessel walls and have limited growth capability, and that outgrowth of ECs from cultures of blood is mostly derived from transplantable marrow-derived cells.
EPCs in humans
First evidence for EPCs in humans originates from patients implanted with a left ventricular assist device by Ra®i et al. (1995) , who demonstrated colonization of thē ow surface of its titanium housing with CD34 1 endothelial-like cells 6 months after the devices were removed. This study suggest that transplanted EPCs residing in the bone marrow are mobilized to the circulation and incorporate in active sites of new vessel formation. Recently, Murohara et al. (2000) have isolated EPCs from umbilical cord blood, a valuable and very simple source of EPCs. These cells incorporated acetylated LDL, released nitric oxide, expressed VE-cadherin, CD31 and vWF and may become a useful strategy in therapeutic approaches by means of EPCs.
Postnatal vasculogenesis as a mechanism of vascular tumor growth
Tumors are endowed with angiogenic capability and their growth, invasion and metastasis are angiogenesis-dependent (Ribatti et al., 1999) . The current thinking is that tumor angiogenesis starts only when the neoplastic mass reaches 1 mm in diameter and when hypoxia occurs and that it is essentially mediated by angiogenic molecules elaborated by tumor cells (Folkman, 1995) . Nevertheless, the mechanisms responsible for vascularization of in situ tumors and their remodeling are still poorly understood and recent histomorphological studies indicate that some tumors may be vascularized without signi®cant angiogenesis, probably by using existing vessels (Pezzella et al., 1997) , or even by forming vascular channels on their own through a non-endothelial cell process designated as`vascular mimicry' (Maniotis et al., 1999) . Pezzella et al. (1997) were the ®rst to describe a nonsmall-lung carcinoma with no morphological evidence of neoangiogenesis that appeared to grow by exploiting normal tissue vessels. They also questioned whether the neoplastic cells were truly non-angiogenic, as suggested by the apparent lack of new vessel formation. An answer to this question may have been given by Maniotis et al. (1999) , who have described a new model of formation of vascular channels by human melanoma cells, called`vasculogenic mimicry', to emphasize the de novo generation of blood vessels without the participation of ECs and independent of angiogenesis. Folberg et al. (2000) wrote that even if`the de novo generation of vascular channels by aggressive and metastatic tumor cells is not strictly a vasculogenetic event' theỳ assigned the name vasculogenetic mimicry to this process'. These authors suggest that tumor cells themselves metamorphose into vessels that either carry blood or connect to the host's blood supply. Highly invasive primary and metastatic melanoma cells may generate vascular channels, lined externally by melanoma cells themselves, that facilitate tumor perfusion independent of angiogenesis. The intreconnected loops and networks, although not typical of angiogenesis, is prototypic of vasculogenesis. It is noteworthy that the work of Maniotis, Folberg and Hendrix has been disputed vigorously by Mc Donald et al. (2000), who considered the evidence presented by Maniotis and coworkers neither persuasive nor novel. Holash et al. (1999) reported that tumor cells migrate toward existing host organ blood vessels in sites of metastases, or in vascularized organs such as the brain, to initiate blood vessel-dependent tumor growth as opposed to classic angiogenesis. These vessels then regress owing to apoptosis of the constituent ECs, apparently mediated by Ang-2. Finally, at the periphery of the growing tumor mass angiogenesis occurs by cooperative interaction of VEGF and Ang-2. Li et al. (2000) have demonstrated that when the tumor mass contains roughly 100±300 cells, individual cells exhibit a chemotaxis-like growth pattern toward the pre-existing host vasculature prior to any evidence of tumor angiogenesis. Host vessels might secrete signals, such as oxygen or other nutrient gradients, growth factors, or other cytokines, that are chemotactic for the tumor cells. In accord with the notion that tumor vasculature, after the initiation of the socalled angiogenic switch (Hanahan and Folkman, 1996) is characterized by a persistence of immature, rather than differentiated blood vessels, postnatal vasculogenesis may contribute to tumor vascular supply throughout EPCs, which circulate from bone marrow, migrate and differentiate in the stromal environment of tumors (Asahara et al., 1999a,b) .
Regulators of postnatal vasculogenesis
The major regulator of postnatal vasculogenesis seems to be VEGF. Springer et al. (1998) demonstrated that, implantation into mouse leg muscle of myoblasts transduced with VEGF, led to a formation of new vessels similar to those formed during embryonic vasculogenesis. These Authors postulated that localized constant production of high levels of VEGF can led to recruitment of circulating EPCs and induce them to undergo differentiation. Asahara et al. (1999a,b) have observed that VEGF-inducing mobilization of bone marrow-derived EPCs resulted in increased differentiated EPCs in vitro and augmented neovascularization in vivo.
Granulocyte macrophage colony stimulating factor (GM-CSF) stimulates hematopoietic progenitor cells (Socinksi et al., 1988) and myeloid lineage cells (Clark and Kamen, 1987) , as well as non-hematopietic cells including bone marrow stromal cells (Dedhar et al., 1988) , EPCs (Takahashi et al., 1999) and ECs (Bussolino et al., 1989) . In an animal model of hindlimb ischemia, Takahashi et al. (1999) have demonstrated that GM-CSF pretreatment produced a signi®cant increase in the circulating population of EPCs and enhanced their differentiation. Gehling et al. (2000) have showed that AC133 1 cells, when cultured in the presence of VEGF and stem cell growth factor (SCGF), give rise to both hematopoietic and EC lineage.
Insulin may be an important regulator of angioblastic differentiation. Human CD34 1 cells derived from hypoglycemic diabetics produce fewer ECs than those of normoglycemic donors, whereas CD34 1 cells derived from hyperglycemic patients produce more (Tomanek and Schatteman, 2000) .
Whether these growth factors have an in¯uence on EPCs, or even on the hemangioblast is currently unknown and at the present, a speci®c cytokine able to induce a speci®c differentiation of the EPCs has not yet identi®ed.
Postnatal vasculogenesis mechanisms
Very little is known about the behavior of ECs during adult vasculogenesis. Postnatal vasculogenesis is probably governed by the same mechanisms as prenatal vasculogenesis. According to Drake and Little (1999) , tightly regulated vascular fusion by which small-caliber endothelial tubes fuse to enclose a common lumen to form larger vessels is likely a mechanism. These authors de®ned this mechanism as`vascular fusion' and considered it an inherent component of vasculogenesis.
Potential of therapeutic vasculogenesis
In animal models of ischemia EPCs are incorporated into sites of active neovascularization and mobilization of bone marrow-derived EPCs constituting a response to tissue ischemia (Takahashi et al., 1999) . This ®nding that circulating EPCs may home to sites of neovascularization and differentiate into ECs is consistent with a postnatal vasculogenesis and the identi®cation of the chemokines that induce mobilization of EPCs from bone marrow to the peripheral circulation may provide a novel mechanism for their recruitment to sites of vascular trauma and to accelerate vascular healing (Ra®i, 2000) . Moreover, expansion and mobilization of EPCs might represent a mechanism to augment the resident population of ECs competent to respond to administered angiogenic cytokines . Kalka et al. (2000) have demonstrated that after transplantation of EPCs to athymic mice with hindlimb ischemia, blood¯ow recovery and capillary density in the ischemic limb were markedly improved and the rate of limb loss was signi®cantly reduced.
New therapeutic strategies in the treatment of tumors
Preclinical research into tumor angiogenesis has identi®ed several antivascular treatments with impressive ef®cacy in animal models of human cancer (Hagedorn and Bikfalvi, 2000) . In contrast to anti-angiogenic therapy, which involves the prevention of neovascularization, vascular targeting is directed at the existing tumor vasculature (Arap et al., 1998) . Development of ex-vivo expansion techniques for EPCs will be useful to provide suitable coating to deliver toxins to tumor vasculature and generation of neutralizing antibodies to receptors on EPCs will increase our understanding of whether recruitment and incorporation of EPCs in the tumor vascular bed are essential for tumor progression and metastasis (Ra®i, 2000) .
Concluding remarks
Further studies on the interrelation between angiogenesis and vasculogenesis concerning the molecular pathways involved in the regulation of these two processes are needed to secure the comprehensive understanding of the common events involved. In the same time, the potential use of the EPCs in therapeutic regimens to increase angiogenesis in ischemic diseases and to limiting angiogenesis in tumors might be further investigated.
